XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 22,091,353 15,996,713
Common Stock Options Granted    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 13,800,485 13,255,459
Nonvested Restricted Stock Units Outstanding    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 7,386,862 2,587,492
Nonvested Market-based Restricted Stock Units Outstanding Granted    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 904,006 153,762